Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors

Am J Emerg Med. 2017 Feb;35(2):379.e5-379.e6. doi: 10.1016/j.ajem.2016.08.055. Epub 2016 Aug 27.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Benzhydryl Compounds / adverse effects*
  • Benzhydryl Compounds / therapeutic use
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetic Ketoacidosis / diagnosis*
  • Diabetic Ketoacidosis / etiology
  • Diabetic Ketoacidosis / physiopathology
  • Female
  • Glucosides / adverse effects*
  • Glucosides / therapeutic use
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Middle Aged
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors*
  • Treatment Outcome

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Hypoglycemic Agents
  • Insulin
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin